Cargando…

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1

Detalles Bibliográficos
Autores principales:	Wasling, Pontus, Malmeström, Clas, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745716/ https://www.ncbi.nlm.nih.gov/pubmed/31484686 http://dx.doi.org/10.1212/NXI.0000000000000613

Ejemplares similares

Impaired procedural memory in narcolepsy type 1
por: Asp, Amanda, et al.
Publicado: (2022)

Monozygotic twins discordant for narcolepsy type 1 and multiple sclerosis
por: Jennum, Poul J., et al.
Publicado: (2016)

Reduced CSF orexin levels in rats and patients with systemic inflammation: a preliminary study
por: Ogawa, Yasuhiro, et al.
Publicado: (2022)

Rituximab for Sjögren syndrome–associated type II mixed cryoglobulinemic cerebral vasculitis
por: Lioger, Bertrand, et al.
Publicado: (2016)

Narcolepsy and Orexins: An Example of Progress in Sleep Research
por: De la Herrán-Arita, Alberto K., et al.
Publicado: (2011)

Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy
por: Viste, Rannveig, et al.
Publicado: (2017)

The relationship between orexin levels and blood pressure changes in patients with narcolepsy
por: Sieminski, Mariusz, et al.
Publicado: (2017)

Children with Narcolepsy type 1 have increased T‐cell responses to orexins
por: Cogswell, Andrew C., et al.
Publicado: (2019)

Disease exacerbation after rituximab induction in neuromyelitis optica
por: Perumal, Jai S., et al.
Publicado: (2015)

Effective treatment of CLIPPERS with long-term use of rituximab
por: Cipriani, Veronica P., et al.
Publicado: (2018)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis
por: Bodro, Marta, et al.
Publicado: (2020)

CD4(+) T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1
por: Ramberger, Melanie, et al.
Publicado: (2016)

Rituximab during pregnancy in neuromyelitis optica: A case report
por: Miranda-Acuña, Jahir, et al.
Publicado: (2019)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Opsoclonus-Myoclonus Syndrome during Rituximab Treatment for Autoimmune Autonomic Ganglionopathy
por: Dumitrascu, Oana M., et al.
Publicado: (2017)

Refractory IgG4-related intracranial hypertrophic pachymeningitis responded to rituximab
por: Liao, Bing, et al.
Publicado: (2014)

Myelopathy in a patient with leukodystrophy due to CSF1R mutation
por: Ho, Victoria M., et al.
Publicado: (2019)

Repeated treatments with rituximab in a patient with amyloid-like IgM deposition neuropathy
por: Kadoya, Masato, et al.
Publicado: (2016)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Atypical CSF findings in West Nile neuroinvasive disease: A diagnostic and therapeutic conundrum
por: Maiti, Baijayanta, et al.
Publicado: (2014)

Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody–positive encephalitis
por: Orengo, James P., et al.
Publicado: (2015)

Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF
por: Kamourieh, Salwa, et al.
Publicado: (2017)

Blended phenotype of adult-onset Alexander disease and spinocerebellar ataxia type 6
por: Odo, Takashi, et al.
Publicado: (2020)

Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS
por: Vallino, Amélie, et al.
Publicado: (2020)

CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome
por: Barateau, Lucie, et al.
Publicado: (2020)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Novel fukutin mutations in limb-girdle muscular dystrophy type 2M with childhood onset
por: Smogavec, Mateja, et al.
Publicado: (2017)

Plasma orexin‐A levels in patients with delirium
por: Nakashima, Hirotaka, et al.
Publicado: (2019)

Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency
por: Bastianini, Stefano, et al.
Publicado: (2015)

HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy
por: Sakai, Noriaki, et al.
Publicado: (2019)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Pre-treatment of blood samples reveal normal blood hypocretin/orexin signal in narcolepsy type 1
por: Ægidius, Helene M, et al.
Publicado: (2021)

Case Report: Reduced CSF Orexin Levels in a Patient With Sepsis
por: Ogawa, Yasuhiro, et al.
Publicado: (2021)

Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy
por: Ito, Hiroto, et al.
Publicado: (2023)

Deoxyguanosine kinase mutation producing juvenile-onset mitochondrial myopathy
por: Komal, F.N.U., et al.
Publicado: (2018)

Adult-onset leukoencephalopathy with homozygous LAMB1 missense mutation
por: Yasuda, Rei, et al.
Publicado: (2020)

Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system
por: Ayoub, Ikram, et al.
Publicado: (2023)

Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy
por: Zuliani, Luigi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b4m4ecvv35kfmqns1b5ng99pd2